PHARMACOGENETICS OF AROMATASE INHIBITORS (AIS) IN PATIENTS WITH METASTATIC BREAST CANCER

被引：0
|
作者：
Ferraldeschi, R. [1 ]
Arnedos, M. [2 ]
Hadfield, K. [3 ]
Ahern, R.
Drury, S. [4 ]
Roberts, S. [3 ]
Howell, A. [1 ]
Smith, I. [2 ]
Newman, W. [3 ]
Dowsett, M. [5 ]
机构：
[1] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[2] Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England
[3] St Marys Hosp, Manchester M13 0JH, Lancs, England
[4] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
[5] Royal Marsden NHS Trust, Dept Acad Biochem, London, England
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [41] Aromatase Inhibitors and Breast Cancer
    Macedo, Luciana Furtado
    Sabnis, Gauri
    Brodie, Angela
    [J]. STEROID ENZYMES AND CANCER, 2009, 1155 : 162 - 173
  • [42] Aromatase inhibitors in breast cancer
    Hiscox, Stephen
    Davies, Eleri Lloyd
    Barrett-Lee, Peter
    [J]. MATURITAS, 2009, 63 (04) : 275 - 279
  • [43] Longitudinal follow-up of endothelial function in breast cancer survivors on aromatase inhibitors (AIs).
    Blaes, Anne Hudson
    Beckwith, Heather Christine
    Hebbel, Robert P.
    Solovey, Anna S.
    Potter, David
    Yee, Douglas
    Petersen, Ashley
    Vogel, Rachel Isaksson
    Luepker, Russell V.
    Duprez, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations
    Maugeri-Sacca, Marcello
    Barba, Maddalena
    Vici, Patrizia
    Pizzuti, Laura
    Sergi, Domenico
    De Maria, Ruggero
    Di Lauro, Luigi
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 147 (02) : 227 - 235
  • [45] DOES METRONOMIC CHEMOTHERAPY REVERSE RESISTANCE TO AROMATASE INHIBITORS IN METASTATIC BREAST CANCER?
    Meng, T. Wai
    Tan, I. B.
    Tan, D. S.
    Ngeow, J.
    Tracy, W.
    Kanesvaran, R.
    Wan, W. Zee
    Tin, S. Lay
    John, C.
    Soon, W. Nan
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 64 - 64
  • [46] Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations
    Marcello Maugeri-Saccà
    Maddalena Barba
    Patrizia Vici
    Laura Pizzuti
    Domenico Sergi
    Ruggero De Maria
    Luigi Di Lauro
    [J]. Breast Cancer Research and Treatment, 2014, 147 : 227 - 235
  • [47] Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer
    Arnedos, M.
    Drury, S.
    Afentakis, M.
    Hills, M.
    Salter, J.
    Smith, I. E.
    Dowsett, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Aromatase Inhibitors as Solely Treatment in Postmenopausal Breast Cancer Patients
    Hille, Ursula
    Soergel, Philipp
    Laenger, Florian
    Schippert, Cordula
    Makowski, Lars
    Hillemanns, Peter
    [J]. BREAST JOURNAL, 2012, 18 (02): : 145 - 150
  • [49] Incidence of arthralgia syndrome (AS) related to aromatase inhibitors (AIs) in postmenopausal women with early breast cancer (EBC)
    Maisano, R.
    Maisano, R.
    Azzarello, D.
    Del Medico, P.
    Giannicola, R.
    Giuffre, C.
    Panuccio, V.
    Raffaele, M.
    Zavettieri, M.
    Falzea, A.
    Nardi, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : CP42 - U381
  • [50] Aromatase inhibitors (AIs) are unlikely to improve overall survival in postmenopausal women with stage I breast cancer
    Diab, S
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S241 - S242
12345